Glycopeptide heteroresistance and tolerance in hospital grampositive isolates: "Invisible" phenomena to the clinician with clinical implications?;Heterorresistencia y tolerancia a glueopéptidos en aislados grampositivos en el hospital: ¿fenómenos "invisibles" para el clínico con posible traducción clínica?

Revista Espanola de Quimioterapia

Volumn 22, Issue 4, 2009, Pages 173-179

  Aguilar, L ^a   Jose Gimenez M ^a   Barberan J ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

Author keywords

Daptomycin; Heteroresistance; Teicoplanin; Tolerance; Vancomycin

Indexed keywords

AMINOGLYCOSIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; DALFOPRISTIN; DAPTOMYCIN; GLYCOPEPTIDE; LINEZOLID; METICILLIN; QUINUPRISTIN; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTEREMIA; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENDOCARDITIS; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HOSPITAL PATIENT; IMMUNOCOMPROMISED PATIENT; LENGTH OF STAY; MENINGITIS; NONHUMAN; RELAPSE; REVIEW; STAPHYLOCOCCUS AUREUS; CROSS INFECTION; DRUG EFFECT; EDITORIAL; GRAM POSITIVE INFECTION; HUMAN; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 77956467831     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. González-Romo F, Rubio M, Betriu C, Picazo JJ; Grupo IGP. Prevalencia y tratamiento de las infecciones por grampositivos en los servicios de medicina interna de hospitales españoles: Estudio IGP. Rev Esp Quimioter 2003;16:428-35.
2. Bouza E, Finch R. Infections caused by Gram-positive bacteria: situation and challenges of treatment. Clin Microbiol Infect 2001;7 Suppl 4:iii.
3. Jones RN. Key considerations in the treatment of complicated staphylococcal infections. Clin Microbiol Infect 2008;14 Suppl 2:3-9.
4. http://www.vhebron.es/ac/preventiva/epine/6-epi-ne-1990-2006.pdf
5. Garcia-Leoni ME, Cercenado E, Rodeño P, Bernaldo de Quirós JC, Martinez-Hernandez D, Bouza E. Susceptibility of Streptococcus pneumoniae to penicillin: a prospective microbiological and clinical study. Clin Infect Dis 1992;14:427-35.
6. Eykyn SJ, Gransden WR, Phillips I. The causative organisms of septicaemia and their epidemiology. J Antimicrob Chemother 1990;25 Suppl C:41-58.
7. Bouza E, Pintado V, Rivera S, Blázquez R, Muñoz P, Cercenado E et al. Nosocomial bloodstream infections caused by Streptococcus pneumoniae. Clin Microbiol Infect 2005;11:919-24.
8. Moellering RC Jr. Problems with antimicrobial resistance in gram-positive cocci. Clin Infect Dis 1998;26:1177-8.
9. French GL. Bactericidal agents in the treatment of MRSA infections-the potential role of daptomycin. J Antimicrob Chemother 2006;58:1107-17.
10. Howe RA, Monk A, Wootton M, Walsh TR, Enright MC. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis 2004;10:855-7.
11. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003;47:3040-5.
12. Khosrovaneh A, Riederer K, Saeed S, Tabriz MS, Shah AR, Hanna MM et al. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2004;38:1328-30.
13. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007;44:1208-15.
14. Lentino JR, Narita M, Yu VL. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis 2008;27:3-15.
15. Tenover FC, Weigel LM, Appelbaum PC, McDougal LK, Chaitram J, McAllister S et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 2004;48:275-80. (Pubitemid 38040208)
16. Clinical and Laboratory Standards Institute/NCCLS. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLSI/NCCLS document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2009.
17. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200. (Pubitemid 351269157)
18. Picazo JJ, Betriu C, Culebras E, Rodríguez-Avial I, Gomez M, López F; VIRA Study Group. Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centers. Diagn Microbiol Infect Dis 2009;64:448-51.
19. Gould IM. The problem with glycopeptides. Int J Antimicrob Agents 2007;30:1-3.
20. Garnier F, Chainier D, Walsh T, Karlsson A, Bolmström A, Grelaud C et al. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J Antimicrob Chemother 2006;57:146-9.
21. Sader HS, Watters AA, Fritsche TR, Jones RN. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis 2007;7:29.
22. Cuevas O, Cercenado E, Bouza E, Castellares C, Trincado P, Cabrera R et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus in Spain: a multicentre prevalence study (2002). Clin Microbiol Infect 2007;13:250-256.
23. Picazo JJ, Betriu C, Rodriguez-Avial I, Culebras E, Gómez M, López F; Grupo VIRA. Vigilancia de resistencias a los antimicrobianos: studio VIRA 2006. Enferm Infecc Microbiol Clin 2006;24:617-28.
24. Wong SS, Ho PL, Woo PC, Yuen KY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 1999;29:760-7.
25. Nunes AP, Schuenck RP, Bastos CC, Magnanini MM, Long JB, Iorio NL et al. Heterogeneous resistance to vancomycin and teicoplanin among Staphylococcus spp. isolated from bacteremia. Braz J Infect Dis 2007;11:345-50.
26. Oteo J, Cuevas O, Navarro C, Aracil B, Campos J; Spanish Group of The European Antimicrobial Resistance Surveillance System (EARSS). Trends in antimicrobial resistance in 3469 enterococci isolated from blood (EARSS experience 2001-06, Spain): increasing ampicillin resistance in Enterococcus faecium. J Antimicrob Chemother 2007;59:1044-5.
27. Alam MR, Donabedian S, Brown W, Gordon J, Chow JW, Zervos MJ et al. Heteroresistance to vancomycin in Enterococcus faecium. J Clin Microbiol 2001;39:3379-81.
28. Khan SA, Sung K, Layton S, Nawaz MS. Heteroresistance to vancomycin and novel point mutations in Tn1546 of Enterococcus faecium ATCC 51559. Int J Antimicrob Agents 2008;31:27-36.
29. Qu TT, Zhang JL, Zhou ZH, Wei ZQ, Yu YS, Chen YG et al. Heteroresistance to teicoplanin in Enterococcus faecium harboring the vanA gene. J Clin Microbiol 2009 Oct 21. [Epub ahead of print].
30. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004;38:448-51.
31. Ruef C. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection 2004;32:315-27.
32. Howden BP. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA). Intern Med J 2005;35 Suppl 2:S136-40.
33. Fong RK, Low J, Koh TH, Kurup A. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur J Clin Microbiol Infect Dis 2009;28:983-7.
34. Bae IG, Federspiel JJ, Miró JM, Woods CW, Park L, Rybak MJ et al. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis 2009;200:1355-66.
35. Bourgeois I, Pestel-Caron M, Lemeland JF, Pons JL, Caron F. Tolerance to the glycopeptides vancomycin and teicoplanin in coagulase-negative staphylococci. Antimicrob Agents Chemother 2007;51:740-3.
36. Sader HS, Fritsche TR, Jones RN. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother 2006;50:2330-6.
37. Traczewski MM, Katz BD, Steenbergen JN, Brown SD. Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007. Antimicrob Agents Chemother 2009;53:1735-8.
38. Sader HS, Jones RN, Rossi KL, Rybak MJ. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. J Antimicrob Chemother 2009;64:1024-8.
39. Perry JD, Jones AL, Gould FK. Glycopeptide tolerance in bacteria causing endocarditis. J Antimicrob Chemother 1999;44:121-4.
40. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006;42 Suppl 1:S13-24.
41. Cercenado E. Staphylococcus lugdunensis: un estafilococo coagulasa-negativo diferente de los demas. Enferm Infecc Microbiol Clin 2009;27:139-42.
42. Frank KL, Del Pozo JL, Patel R. From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis. Clin Microbiol Rev 2008;21:111-33.
43. Saribas S, Bagdatli Y. Vancomycin tolerance in enterococci. Chemotherapy 2004;50:250-4.
44. Novak R, Henriques B, Charpentier E, Normark S, Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 1999 Jun 10;399(6736):590-3.
45. Gillis LM, White HD, Whitehurst A, Sullivan DC. Vancomycin-to-lerance among clinical isolates of Streptococcus pneumoniae in Mississippi during 1999-2001. Am J Med Sci 2005;330:65-8.
46. Hidalgo M, Castaneda E, Arias CA. Tolerance to vancomycin in a multiresistant, Colombian isolate of Streptococcus pneumoniae. J Antimicrob Chemother 2003;52:300-2.
47. Sung H, Shin HB, Kim MN, Lee K, Kim EC, Song W et al. Vancomycin-tolerant Streptococcus pneumoniae in Korea. J Clin Microbiol 2006;44:3524-8.
48. Henriques Normark B, Novak R, Ortqvist A, Kallenius G, Tuomanen E, Normark S. Clinical isolates of Streptococcus pneumoniae that exhibit tolerance of vancomycin. Clin Infect Dis 2001;32:552-8.
49. Rodriguez CA, Atkinson R, Bitar W, Whitney CG, Edwards KM, Mitchell L et al. Tolerance to vancomycin in pneumococci: detection with a molecular marker and assessment of clinical impact. J Infect Dis 2004;190:1481-7.
50. Antón N, Blázquez R, Gómez-Garcés JL, Alós JI. Study of vancomycin tolerance in 120 strains of Streptococcus pneumoniae isolated in 1999 in Madrid, Spain. J Antimicrob Chemother 2001;47:902-3.
51. Ortega M, Marco F, Soriano A, García E, Martinez JA, Mensa J. Lack of vancomycin tolerance in Streptococcus pneumoniae strains isolated in Barcelona, Spain, from 1999 to 2001. Antimicrob Agents Chemother 2003;47:1976-8.
52. Rolston KV, Chandrasekar PH, LeFrock JL. Antimicrobial tolerance in group C and group G streptococci. J Antimicrob Chemother 1984;13:389-92.
53. Zaoutis T, Schneider B, Steele Moore L, Klein JD. Antibiotic susceptibilities of group C and group G streptococci isolated from patients with invasive infections: evidence of vancomycin tolerance among group G serotypes. J Clin Microbiol 1999;37:3380-3.
54. The choice of antibiotic agents. Med Lett 1992;34:49-56.
55. Moellering RC Jr. The Garrod Lecture. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother 1991;28:1-12.
56. Faville RJ Jr, Zaske DE, Kaplan EL, Crossley K, Sabath LD, Quie PG. Staphylococcus aureus endocarditis. Combined therapy with vancomycin and rifampin. JAMA 1978;240:1963-5.
57. Sorrell TC, Packham DR, Shanker S, Foldes M, Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982;97:344-50.
58. May J, Shannon K, King A, French G. Glycopeptide tolerance in Staphylococcus aureus. J Antimicrob Chemother 1998;42:189-97.
59. Gopal V, Bisno AL, Silverblatt FJ. Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations. JAMA 1976;236:1604-6.
60. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 004;42:2398-402.
61. Safdar A, Rolston KV. Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer. Cancer 2006;106:1815-20.
62. McCullers JA, English BK, Novak R. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 2000;181:369-73.
63. Aguilar L, Barberán J, Prieto J, Gimenéz M. Optimización de la actividad bactericida en el tratamiento hospitalario de infecciones por grampositivos. Rev Esp Quimioter 2008;21:37-44.
64. Alder J, Eisenstein B. The advantage of bactericidal drugs in the treatment of infection. Curr Infect Dis Rep 2004;6:251-3.
65. González C, Rubio M, Romero-Vivas J, González M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29:1171-7.
66. Cafini F, Aguilar L, González N, Gimenez MJ, Torrico M, Alou L et al. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives. J Antimicrob Chemother 2007;59:1185-9.
67. Alou L, Aguilar L, Gimenez MJ, Torrico M, Sevillano D. Activity of serum concentrations of daptomycin vs. vancomycin against vancomycin-susceptible and resistant Enterococcus faecium in the presence of albumin physiological concentrations: an in vitro pharmacodynamic simulation. Eur J Clin Microbiol Infect Dis 2008;27:1009-11.
68. Torrico M, Giménez MJ, González N, Alou L, Sevillano D, Cafini F et al. Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus with daptomycin MICs of 1-2 μg/ml. Int J Antimicrob Agents (En prensa).
69. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006;44:3883-6.
70. Moise PA, Smyth DS, El-Fawal N, Robinson DA, Holden PN, Forrest A et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008;61:85-90.
71. Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006;57:699-704.
72. Domenech A, Ribes S, Cabellos C, Dominguez MA, Montero A, Liñares J et al. A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections. Microb Drug Resist 2004;10:346-53.